Loading cancer entity…
Loading cancer entity…
Clinical trials
298 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06866574 | A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males | active not recruiting | Phase 3 | 9,300 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06236464 | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas | recruiting | — | 170 | National Cancer Institute, NaplesOTHER | 1 | Jul 29, 2025 |
| clinicaltrials |
| NCT02059499 | Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions | completed | Phase 3 | 91 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 23, 2025 | clinicaltrials |
| NCT07059442 | Screening for Anal Cancer and Precancer in Women With HIV (SANCA)(SANCA) | not yet recruiting | N/A | 1,000 | Karolinska InstitutetOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02785263 | Shared Decision Making With Anal Cancer Patients on Radiation Dose(PC-Anal-01) | completed | N/A | 27 | Vejle HospitalOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT03519295 | A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma(SCARCE) | completed | Phase 2 | 97 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07021378 | Tolerance to Immunomodulatory Nutritional Therapy in Oncology Patients Undergoing Chemotherapy and Radiotherapy(NESTLE) | completed | N/A | 16 | D'Or Institute for Research and EducationOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT00324415 | Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer | completed | Phase 2 | 45 | AIDS Malignancy ConsortiumNETWORK | 1 | May 30, 2025 | clinicaltrials |
| NCT05555862 | Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL(anal HSIL HIV-) | active not recruiting | Phase 2 | 17 | Frantz Viral Therapeutics, LLCINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT03061435 | Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.(Vulvar-AIN) | recruiting | N/A | 110 | Dr. Danielle VicusOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04328740 | Phase 1 Study of Oral TP-1454 | completed | Phase 1 | 31 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05266898 | Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV(AGO-Gard) | recruiting | Phase 4 | 250 | Louisiana State University Health Sciences Center in New OrleansOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06630793 | IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer(IMPAC) | recruiting | N/A | 108 | Tata Memorial CentreOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04462042 | Proton Versus Photon Therapy in Anal Squamous Cell Carcinoma(SWANCA) | recruiting | N/A | 100 | Umeå UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT01937780 | Anal Cancer Radiotherapy Study(ANCARAD) | active not recruiting | — | 75 | Oslo University HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05939401 | A Study Regarding Tissue Response During and After Treatment for Anal Cancer(ANCABio) | recruiting | — | 400 | Sahlgrenska University HospitalOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT04276935 | Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions | completed | — | 20 | AIDS Malignancy ConsortiumNETWORK | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06697964 | High Resolution Anuscopy Study | recruiting | — | 500 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06792604 | Host Genome Methylation: a Screening Tool in Anal Cancer Detection(AMethysT) | recruiting | N/A | 770 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06562140 | Multidimensional Examination of Patients with Colorectal and Anal Cancer(MECACP) | unknown | — | 300 | University of PecsOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05060471 | PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients | completed | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT03489707 | The Prevent Anal Cancer Self-Swab Study | completed | N/A | 253 | Medical College of WisconsinOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT02199236 | Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT05959564 | A Chatbot Intervention for Reducing HPV Vaccine Hesitancy | completed | N/A | 456 | University of Maryland, College ParkOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06619743 | HPV Infection and Vaginal Microecology in Immunosuppressed Women | not yet recruiting | — | 10,000 | Lan ZhuOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT03018418 | Proton Therapy in Reducing Toxicity in Anal Cancer | unknown | Phase 2 | 14 | Jordan KharofaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05385250 | Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II(DACG-II) | unknown | N/A | 100 | Karen-Lise Garm SpindlerOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT05570279 | PLAN-A Data- Bio- and Plan- Bank Collection for SCCA in Denmark(PLAN-A) | unknown | — | 314 | Aarhus University HospitalOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05572801 | NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer | recruiting | N/A | 400 | Aarhus University HospitalOTHER | 4 | Aug 14, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02135419 | Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions(ANCHOR) | completed | Phase 3 | 4,446 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 26, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT04055142 | Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males(TreatAIN) | completed | Phase 3 | 108 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | terminated | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04090060 | The Prevent Anal Cancer Palpation Study | completed | N/A | 718 | Medical College of WisconsinOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05578820 | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | completed | Phase 1 | 21 | Gene Surgery LLCINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05518201 | Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06327568 | Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens | recruiting | — | 200 | European Institute of OncologyOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT03856437 | A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination | completed | N/A | 1,170 | University of Maryland, College ParkOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03051516 | HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions | terminated | Phase 4 | 188 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05130073 | 4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer | completed | — | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 31, 2025source: clinicaltrials